Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled,...
Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial
About this item
Full title
Author / Creator
Cadavid, Diego, Dr , Balcer, Laura, Prof , Galetta, Steven, Prof , Aktas, Orhan, Prof , Ziemssen, Tjalf, Prof , Vanopdenbosch, Ludo, MD , Frederiksen, Jette, Prof , Skeen, Mark, MD , Jaffe, Glenn J, Prof , Butzkueven, Helmut, Prof , Ziemssen, Focke, Prof , Massacesi, Luca, Prof , Chai, Yi, PhD , Xu, Lei, PhD , Freeman, Stefanie, MD and RENEW Study Investigators
Publisher
England: Elsevier Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: Elsevier Ltd
Subjects
More information
Scope and Contents
Contents
Summary Background The human monoclonal antibody opicinumab (BIIB033, anti-LINGO-1) has shown remyelinating activity in preclinical studies. We therefore assessed the safety and tolerability, and efficacy of opicinumab given soon after a first acute optic neuritis episode. Methods This randomised, double-blind, placebo-controlled, phase 2 study (RE...
Alternative Titles
Full title
Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial
Authors, Artists and Contributors
Author / Creator
Balcer, Laura, Prof
Galetta, Steven, Prof
Aktas, Orhan, Prof
Ziemssen, Tjalf, Prof
Vanopdenbosch, Ludo, MD
Frederiksen, Jette, Prof
Skeen, Mark, MD
Jaffe, Glenn J, Prof
Butzkueven, Helmut, Prof
Ziemssen, Focke, Prof
Massacesi, Luca, Prof
Chai, Yi, PhD
Xu, Lei, PhD
Freeman, Stefanie, MD
RENEW Study Investigators
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_1872845630
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1872845630
Other Identifiers
ISSN
1474-4422
E-ISSN
1474-4465
DOI
10.1016/S1474-4422(16)30377-5
